As pharmaceutical giants race to capture share in the booming GLP-1 market, a $4 billion biotech company is quietly approaching its “moment of truth.”
Viking Therapeutics (VKTX) does not yet have an approved product on the market. But its lead pipeline asset, VK2735, is approaching a critical inflection point. The company is expected to release clinical data in the third quarter of this year evaluating the drug as a maintenance dose. If the results are positive, this small-cap player could not only see a near-term surge in its share price but also potentially carve out a meaningful slice of a market currently dominated by Novo Nordisk and Eli Lilly.
Investors often describe Viking’s situation as a “binary” outcome—success for VK2735 could send shares soaring, while failure could erase much of its value. High risk, high reward lies at the core of this biotech stock.
The injectable version of VK2735 is already in Phase 3 trials, and a Phase 3 study for the oral formulation is expected to begin later this year. Perhaps more notably, Viking is exploring the drug’s potential as a maintenance therapy—allowing patients who have already achieved significant weight loss to transition to VK2735 for long-term management. If validated, this strategy could significantly expand the drug’s addressable market.
Unlike many biotech companies still years away from pivotal readouts, Viking’s next catalyst is measured in months. Based on what the company describes as “exciting early data,” it initiated a study assessing VK2735 for maintenance dosing, covering both monthly injections and daily or weekly oral formulations. The data expected in the third quarter will serve as the first major test of this strategy’s viability.
The GLP-1 market is widely projected to reach $100 billion in annual sales by the start of the next decade, with oral formulations expected to drive much of that growth. Against this backdrop, Viking’s relatively small size becomes a strategic advantage.
With a market capitalization of just $4 billion—a fraction of Novo Nordisk’s and Eli Lilly’s multi-hundred-billion-dollar valuations—Viking is a compelling acquisition target for larger pharmaceutical companies looking to expand their metabolic portfolios. Some analysts suggest that if VK2735 continues to deliver positive data, Viking could receive a premium buyout offer, with a valuation three times its current level not out of the question. The stock traded near $100 per share at one point in the past, compared to its current price around $32.
Viking shares are down 6% year-to-date in 2026 and have retreated 24% from their 52-week high. The company is not yet profitable, reporting a net loss of $359.6 million last year, and its prospects are almost entirely tied to VK2735. This is a classic “all-or-nothing” investment, where any setback in clinical data could trigger sharp downside.
For risk-tolerant investors, however, the current pullback may offer an entry point ahead of a major catalyst. In a crowded but still red-hot GLP-1 space, few small-cap names offer this combination of near-term binary event risk and differentiated positioning. Whatever the outcome, Viking Therapeutics is set to face its moment of truth in the third quarter of this year.
